You are here

  • Home
  • Archive
  • Volume 75, Issue Suppl 2
  • THU0123 Non-Medical Switch from Originator To Biosimilar Infliximab among Patients with Inflammatory Rheumatic Disease – Impact on S-Infliximab and Antidrug-Antibodies. Results from The National Danish Rheumatologic Biobank and The Danbio Registry

Citation Tools

Article menu
Download PDFPDF
Poster Presentations
Rheumatoid arthritis - anti-TNF therapy
THU0123 Non-Medical Switch from Originator To Biosimilar Infliximab among Patients with Inflammatory Rheumatic Disease – Impact on S-Infliximab and Antidrug-Antibodies. Results from The National Danish Rheumatologic Biobank and The Danbio Registry

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Glintborg B, Kringelbach T, Høgdall E, et al
THU0123 Non-Medical Switch from Originator To Biosimilar Infliximab among Patients with Inflammatory Rheumatic Disease – Impact on S-Infliximab and Antidrug-Antibodies. Results from The National Danish Rheumatologic Biobank and The Danbio Registry
Annals of the Rheumatic Diseases 2016;75:224.